Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
When Alzheimer’s disease is diagnosed too late—in moderate to severe stages—patients miss the window to benefit from the newest disease-modifying drugs. The FDA has approved lecanemab and donanemab, medications that can slow cognitive decline by 27 to 35 percent over 18 months, but only for people with mild cognitive impairment (MCI) or mild dementia who have confirmed amyloid plaques in their brains. A 72-year-old woman who didn’t notice her forgetfulness until she repeatedly forgot her grandchildren’s names and couldn’t manage her medications missed eligibility for these drugs by the time her family pushed for a diagnosis three years into cognitive decline.
By then, her disease had progressed beyond the therapeutic window. The critical problem is timing. Current biomarker research shows that amyloid accumulation in the brain begins 10-20 years before any cognitive symptoms appear, and the FDA-approved medications work best when started during the MCI stage or very early dementia—before substantial neuronal damage has occurred. Missing this window means relying on older symptom-management drugs that don’t slow disease progression, only mask some of its effects.
Table of Contents
- Why Early Detection and Diagnosis Matter for Drug Eligibility
- The Biomarker Revolution and Diagnostic Thresholds
- Treatment Efficacy and What “Too Late” Really Means
- The Statistics of Late Diagnosis in Real Numbers
- Eligibility Barriers and Coverage Complications
- The Clinical Pipeline and Future Options
- What Happens Practically When Diagnosis Is Delayed
Why Early Detection and Diagnosis Matter for Drug Eligibility
The FDA’s approval of lecanemab (Leqembi) in January 2023 and donanemab (Kisunla) in July 2024 created a time-sensitive opportunity for people with early-stage Alzheimer’s. However, eligibility is strict and stage-dependent. Lecanemab and donanemab are only approved for people with MCI or mild dementia due to Alzheimer’s disease who have confirmed elevated beta-amyloid in their brains. A person diagnosed with moderate dementia—even if they have the same amyloid pathology—does not qualify for these treatments because clinical trials only studied their safety and efficacy in earlier stages.
The diagnostic window is narrow and shrinking. Among people with MCI, about 15 percent develop dementia after two years, and 32 percent within five years. Once someone crosses into moderate or severe dementia, the structural brain damage has progressed too far for the available anti-amyloid drugs to be effective. A 68-year-old man who had MCI for three years without a formal diagnosis missed lecanemab eligibility; by the time his cognition declined enough to prompt testing, advanced neurodegeneration was already visible on brain scans. His neurologist explained he had likely passed the therapeutic window during those three undiagnosed years.
The Biomarker Revolution and Diagnostic Thresholds
Blood biomarkers have revolutionized early diagnosis, though most people don’t know they exist. The FDA cleared the first blood tests for Alzheimer’s biomarkers in 2024, and these tests now match PET scan results more than 90 percent of the time for detecting amyloid. Elevated phosphorylated-tau181, phosphorylated-tau217, and neurofilament light chain (NfL) in blood all predict faster progression from normal cognition to MCI, and from MCI to dementia. This means a person can have biological Alzheimer’s disease—confirmed by blood tests—while still appearing cognitively normal or minimally impaired.
The diagnostic criteria adopted by the Alzheimer’s Association and NIH require evidence of both amyloid pathology and neurodegeneration to diagnose MCI due to Alzheimer’s. The two-part requirement is essential: someone with only amyloid plaques but no neuronal damage might never progress to symptomatic disease, while someone with only neurodegeneration but no amyloid likely has a different type of cognitive disorder. By the time a person shows both biomarkers plus cognitive symptoms, the disease has been silently progressing for years. A critical limitation is that many primary care physicians have not been trained in these newer biomarker-based criteria, and some patients wait months for a neurology referral, during which disease progression continues unchecked.
Treatment Efficacy and What “Too Late” Really Means
The clinical data for lecanemab and donanemab show meaningful but modest benefits. Lecanemab slowed cognitive decline by 27 percent over 18 months, while donanemab achieved approximately 35 percent slowing, corresponding to a 4.5 to 7.5 month delay in disease progression. These percentages sound encouraging, but they’re measured against placebo decline—and the benefits are most apparent when started early, before extensive neuronal loss. Once diagnosed with moderate dementia, a person’s remaining cognitive capacity is already significantly compromised, and the medications have not been studied in this population.
The side effects of these drugs also matter more in advanced disease. Amyloid-related imaging abnormalities (ARIA), including brain swelling or microhemorrhages, occur in approximately 1 in 5 patients taking lecanemab. People with genetic risk (carrying the ApoE4 gene variant) have higher risk of ARIA-related bleeding. A patient diagnosed after cognitive decline is severe faces both the higher risk of side effects and the lower likelihood of benefiting from the drug’s disease-slowing effect. Additionally, long-term effectiveness beyond the 18-month trial period is still being established through ongoing monitoring; these are not cures but rather modest slowing agents that may buy time only if started early enough.
The Statistics of Late Diagnosis in Real Numbers
Late diagnosis is common. An estimated 7.4 million Americans age 65 and older currently live with clinical Alzheimer’s dementia, but many were diagnosed only after cognitive decline became undeniable to family members or employers. Alzheimer’s disease deaths increased 134 percent between 2000 and 2024, rising to 116,022 recorded deaths in 2024 alone. The disease is now the fifth-leading cause of death among people 65 and older. These numbers reflect not only disease progression but also the reality that many diagnoses come too late for early interventions.
The Alzheimer’s Association’s recent update to diagnostic guidelines emphasizes that physicians, families, and patients themselves must be alert for early cognitive changes—the memory problems that are brushed off as normal aging, the confusion with medications, the difficulty with finances or appointments. The previous U.S. diagnostic guidelines had not been updated in over 20 years, meaning many clinicians trained before 2024 may not yet know about blood biomarkers or the expanded eligibility for newer treatments. A 76-year-old woman whose doctor attributed her memory complaints to stress was not screened for amyloid biomarkers until two years later, when her family requested a comprehensive neurological evaluation. By then, she was already showing moderate cognitive decline on formal testing, making her ineligible for the newest medications.
Eligibility Barriers and Coverage Complications
Even when patients are diagnosed early enough to qualify for lecanemab or donanemab, access remains complicated. Medicare covers both medications, but many private insurance companies have denied coverage, arguing that the modest slowing of disease progression does not justify the cost and burden of IV or subcutaneous infusions. A person with MCI due to Alzheimer’s and confirmed amyloid may find themselves ineligible for treatment not because of their disease stage, but because of insurance coverage decisions. Additionally, the newer formulations—including the August 2025 FDA approval of Leqembi IQLIK, a once-weekly subcutaneous injection for self-administration at home—may simplify treatment logistics, but availability and insurance approval timelines vary.
The FDA has also approved maintenance dosing schedules to reduce treatment burden. In January 2025, the FDA approved a less-frequent maintenance schedule for IV lecanemab (every 4 weeks instead of every 2 weeks after initial loading), and home-based subcutaneous weekly injections are now available. However, the initial starter doses for home use still require a decision expected in May 2026. A 70-year-old patient diagnosed with early MCI might be eligible for the newer home-based formulation, but a nearby neighbor with the same diagnosis at the same time might only have access to office-based infusions, depending on their insurance plan and whether the treating neurology clinic offers the latest formulations.
The Clinical Pipeline and Future Options
The Alzheimer’s drug development pipeline now includes 138 medications being tested in 182 clinical trials. Several new candidates are moving toward FDA decisions in 2026. MK-2214, which targets tau protein accumulation, has been granted Fast Track Designation. Trontinemab, another next-generation amyloid-targeting drug, recently entered Phase III trials.
AXS-05 for Alzheimer’s disease agitation, a behavioral symptom common in moderate to late-stage disease, has been accepted for Priority Review with an FDA decision expected April 30, 2026. Yet even as the pipeline grows, a person diagnosed today with moderate dementia will likely not see the benefits of these drugs, as new approvals typically focus on extending treatment to the earliest disease stages or managing symptoms rather than providing dramatic improvements for advanced disease. The drugs already approved and in development do not reverse cognitive damage—they slow future decline. Once that damage is extensive, these medications cannot restore lost cognitive function.
What Happens Practically When Diagnosis Is Delayed
When Alzheimer’s is diagnosed too late, the practical consequences unfold over months. A person with moderate dementia typically cannot safely live alone, triggering rapid changes in living arrangements, financial decisions, and family dynamics. Care costs skyrocket—full-time in-home care or assisted living can exceed $10,000 per month, whereas early diagnosis and treatment might allow someone to remain independent and cognitively functional in their own home longer. The newest medications, when started in MCI, may preserve independence and delay institutionalization, potentially extending meaningful years with family and familiar routines. Legal and financial planning also suffers from late diagnosis.
Someone diagnosed with moderate dementia may no longer have the cognitive capacity to execute a durable power of attorney, update a will, or make informed healthcare decisions. Early diagnosis, by contrast, allows the person to participate in these decisions while still mentally capable. A 75-year-old man diagnosed with mild dementia could name his son as healthcare proxy and financial power of attorney, preserving his autonomy in decision-making. His neighbor, diagnosed one year later with moderate dementia, had already lost the legal capacity to make these changes, forcing his adult children into more complex and costly guardianship proceedings. Beyond the immediate medical question of drug eligibility lies the broader life question of time—time to plan, prepare, and maintain agency while cognitive function remains.
- —
